65,437 trials
Migraine
Primary: Number of Subjects Who Were Pain Free at 2 Hours Post Treatment With Study Drug. — 4; 8 participants — p=0.289
Asthma
Primary: Rate of Asthma Exacerbations Over the 48 Week Treatment Period — 0.88; 0.66 exacerbation/patient-week
HIV Infections
Primary: Percent of Participants With Primary Safety Endpoint — 0; 0; 0; 0 percentage of participants
Infections, Papillomavirus
Primary: Number of Subjects Reporting Any Serious Adverse Event (SAE) and SAE(s) With a Causal Relationship to Vaccination as Assessed by the Investigator. — 3; 0 Subjects
Healthy Contact Lens Wearers
Primary: Subjective Acceptance — 1.9; 2.1 units on a scale
Cervical Dystonia
Primary: Pre- and Post-injection Toronto Western Spasmodic Torticollis Rating Scale(TWSTRS): Global Clinical Impression Scale (GCI); Visual Analog Scale(VAS)
Histological or Cytological Diagnosis of Locally Advanced or Metastatic NSCLC of Nonsquamous Histology and Not Amenable to Curative Therapy.
Primary: Progression Free Survival (PFS) — 2.9; 3.2 months — p=0.0047
Asthma
Primary: Number of Participants With an Asthma-related Event Occurring Between 1 and 6 Months Following the Index Event — 915 participants — p=<0.0001
Magnetic Resonance Imaging
Primary: Number of Participants With Diagnostic Adequacy - Open-label Clinical Investigators (Per Protocol Set) — 1; 0; 2; 3 Participants
Neoplasms, Breast
Primary: Number of Participants With Pathological Complete Response (pCR) at the Time of Surgery — 38; 44; 78 participants — p=0.3416
Vitamin A Deficiency · Maternal Mortality · Infant Mortality
Primary: All-cause, Pregnancy-related Mortality — 41; 47; 50 Participants — p=0.05
Vasomotor Symptoms
Primary: Number of Participants With Nausea During the First 2 Weeks of Treatment — 24; 31; 28; 43 Participants — p=0.024
Healthy
Primary: Maximum Plasma Concentration (Cmax) — 270.31; 248.46 ng / ml
Anorexia Nervosa
Primary: Percent Change in Spine Bone Density Over the Study Duration (18 Months) — 2.6; 0.3 Percent change — p=<0.05
Influenza
Primary: Number of Randomized Participants Reporting Local and Systemic Reactions. — 52; 37; 24; 19 Subjects